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More than 150 years from the initial description of inflammation in atherosclerotic plaques, randomized clinical trials to test anti-inflammatory
therapies in atherosclerosis have recently been initiated. Lymphocytes and macrophages are main participants in the inflammatory response in
atherosclerosis. T lymphocytes operate mainly by exerting strong influences on the function of many cells in the immune system and beyond,
and co-ordinating their interactions. Importantly, T lymphocytes are not a homogenous population, but include several subsets with specialized
functions that can either promote or suppress inflammation. The interactions between these T-lymphocyte subsets have critical consequences
on the course and outcome of inflammation. The complexity of the inflammatory response in atherosclerosis poses significant challenges on
translating experimental findings into clinical therapies and makes the journey from bench to bedside an arduous one. Here, we summarize
recent advances on the role of CD4+ T cells in the inflammatory process in atherosclerosis and discuss potential therapies to modulate these
lymphocytes that may provide future breakthroughs in the treatment of atherosclerosis.
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Introduction
Atherosclerosis was initially considered a disease exclusively caused
by cholesterol deposition in the arterial wall. Significant evidence
demonstrated that atherosclerotic plaques are not passive collec-
tions of lipids, but sites of active interactions between cells of the
immune system and vascular cells that influence the fate of athero-
mas.1 As evidenced in several studies in animal models and patients,
both innate and adaptive immune cells participate in this process
and have significant effects on the initiation and progression of
atherosclerotic lesions.2,3 Interactions between immune and vascu-
lar cells trigger a self-perpetuating inflammatory cycle that generates
a chronic inflammatory milieu that promotes atherosclerotic
plaque growth and rupture.1 The hypothesis that inflammation is a
significant driving factor in atherosclerosis is now the focus of phase
III clinical trials that test strategies to reduce inflammatory media-
tors.4 On-going phase III trials target the innate inflammatory
cytokines interleukin-1b (IL-1b; targeted with Canakinumab, a hu-
man monoclonal anti-IL-1b antibody in the CANTOS trial), IL-6,
and tumour necrosis factor-a (TNF-a; targeted with low-dose
methotrexate in the CIRT trial). The immune response in
atherosclerosis is multifaceted and, in addition to innate cells,
adaptive immune responses have significant contributions. Indeed,
adaptive immune cells such as T lymphocytes, B lymphocytes, and
antibodies have been identified in atherosclerotic plaques and circu-
lation of patients with atherosclerosis.5 Moreover, substantial evi-
dence from animal studies clearly demonstrates that specialized
subsets of T and B lymphocytes exert either protective or promot-
ing effects on atherogenesis.2 These data suggest that more targeted
approaches may be required to successfully retune the immune
system and modulate the complex inflammatory response in ath-
erosclerosis. In the following sections, we will summarize recent
advances on the role of CD4+ T lymphocytes in atherosclerosis,
focusing on two subsets [CD4+CD28null and regulatory T (Treg)
cells] that are at opposing poles of the inflammatory process that
underlies atherosclerosis and harbour therapeutic potential.
CD41 T cells in atherosclerosis
T lymphocytes represent the second largest immune cell population
in atherosclerotic plaques after macrophages. Both helper (CD4+)
and cytotoxic (CD8+) T cells have been identified in atheromas.
* Corresponding author. Tel: +44 2087252808, Fax: +44 2087253328, Email: i.dumitriu@sgul.ac.uk
† The first two authors contributed equally to the study.
& The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
European Heart Journal – Cardiovascular Pharmacotherapy
doi:10.1093/ehjcvp/pvw001
 European Heart Journal - Cardiovascular Pharmacotherapy Advance Access published February 21, 2016






However, the inflammatory response in atherosclerosis is domi-
nated by Th1 lymphocytes, the most abundant T-cell subset in pla-
ques. Characteristically, Th1 cells are identified by the production of
interferon-g (IFN-g), a cytokine that promotes atherosclerosis and
plaque rupture through effects on several cells in atherosclerotic
lesions.1 While the pro-atherogenic role of Th1 is well documented,
the precise contribution of other CD4+ T-cell subsets (e.g. Th2 and
Th17) remains debatable due to conflicting reports.2
CD41CD28null T cells
Most naive CD4+ T cells constitutively express the co-stimulatory
receptor CD28, which delivers vital signals that sustain the prolifer-
ation and survival of T cells upon antigen recognition.6 A subset of
CD4+ T cells that lack CD28—known as CD4+CD28null (CD28null)
T cells—has been identified and implicated in several chronic inflam-
matory diseases, including atherosclerosis.7,8 These cells share fea-
tures with Th1 cells, but also diverge phenotypically and functionally
from conventional CD4+CD28+ (CD28+) Th1 lymphocytes
(Figure 1).7,9 Noteworthy, CD28null T cells are more adept at secret-
ing pro-inflammatory cytokines IFN-g and TNF-a than conventional
CD28+ T cells, both in the resting state and following activation.10
We have recently demonstrated that, in patients with acute coron-
ary syndrome (ACS), CD28null T-cell cytokine production is regu-
lated by the alternative co-stimulatory receptors OX40 and
4-1BB6 that were significantly up-regulated on circulating CD28null
compared with CD28+ T cells.10 In addition, CD28null T cells ex-
press and release cytotoxic molecules perforin and granzyme
B.10,11 These molecules, usually restricted to cytotoxic CD8+ T
cells and natural killer cells, have been suggested to enable CD28null
T cells to lyse endothelial cells in vitro.12 We found that, in ACS,
OX40 and 4-1BB regulate not only the cytokine production, but
also the release of perforin from CD28null T cells.10 Another distin-
guishing feature from conventional CD28+ T lymphocytes is the re-
duced sensitivity of CD28null T cells to apoptosis induction. In
rheumatoid arthritis (RA), this has been attributed to an increase
Figure 1 Overview of cardinal features and potential strategies to target CD28null and regulatory T-cell lymphocytes in atherosclerosis.
CD28null T cells expand in the circulation and atherosclerotic plaques in patients with acute coronary syndrome. These cells produce high levels
of inflammatory cytokines (interferon-g and tumour necrosis factor-a) and express and release cytotoxic molecules (perforin and granzyme B).
The production of cytokines and cytotoxic molecules is modulated by co-stimulatory receptors OX40 and 4-1BB, which are up-regulated on
CD28null T cells. Moreover, CD28null T cells are resistant to apoptosis due to reduction in apoptotic molecules Fas, Bim, and Bax, which underlies
the expansion of this cell subset in acute coronary syndrome patients. Several strategies have been proposed to reduce the number and/or func-
tion of CD28null T cells such as tumour necrosis factor-a inhibition, statins, sensitization to apoptosis, and inhibition of co-stimulation (CTLA4-Ig,
anti-OX40, and anti-4-1BB antibodies). Regulatory T cells have crucial roles in counteracting the actions of inflammatory T lymphocytes such as
CD28null T cells. Redundant mechanisms enable regulatory T cells to suppress inflammation and T-cell actions among which are the production of
anti-inflammatory cytokines (interleukin-10 and transforming growth factor-b), CTLA-4-mediated suppression, and interference with metabolic
pathways (conversion of ATP into adenosine, which has anti-inflammatory properties). On-going experimental and clinical work is testing various
strategies to boost the number and/or the function of circulating or intraplaque regulatory T cells such as adoptive transfer of regulatory T cells
expanded in vitro, vaccination protocols that induce expansion of naturally occurring regulatory T cells or conversion of conventional CD4+ T cells
into regulatory T cells, and blockade of inflammatory cytokines (tumour necrosis factor-a and interleukin-6).
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in anti-apoptotic proteins (e.g. Bcl-2),13 while in ACS we found a re-
duction in pro-apoptotic proteins (e.g. Fas, Bim, and Bax).14 Other
characteristics of CD28null T cells have been described elsewhere.9
Whereas circulating CD28null T cells are nearly undetectable in
healthy individuals, this subset expands in patients with ACS,10,15
chronic inflammatory disorders such as autoimmunity (extensively
characterized in RA), chronic infections, and chronic or end-stage
kidney disease.9 Acute coronary syndrome patients show signifi-
cantly higher frequencies of circulating CD28null T cells than healthy
controls or stable angina (SA) patients.10,15 A 4-year follow-up study
found that ACS patients with recurrent myocardial infarction had
four-fold higher circulating CD28null T-cell frequencies compared
with patients with only one acute event and that the expansion of
CD28null T lymphocytes associated with ACS severity and poor out-
come, indicating a pathogenic role for these cells.16 This is also sup-
ported by identification of CD28null T cells not only in the peripheral
circulation but also in atherosclerotic plaques, with preferential
accumulation in unstable lesions.17 As CD28null T cells secrete
IFN-g10,18 and lyse endothelial cells,12 these effector functions
may promote local inflammation and trigger plaque destabilization.
Importantly, RA and other inflammatory diseases associate with
increased ACS incidence and poorer outcome.19 It is tempting to
speculate that CD28null T cells are likely candidates for driving the
accelerated atherosclerosis process observed in these disorders.
Indeed, RA patients with high frequencies of CD28null T lympho-
cytes have increased carotid artery intima-media thickness (IMT)
and decreased flow-mediated vasodilatation than those in whom
this subset does not expand.20 Similarly, the presence of CD28null
T cells in end-stage kidney disease patients has been associated
with increased C-reactive protein and IMT.21 Moreover, CD28null
T-cell expansion in patients with type II diabetes correlates with
ACS occurrence and poor outcome.18
The mechanisms involved in CD28null T-cell expansion in athero-
sclerosis and inflammatory disorders remain poorly understood. It
has been suggested that CD28 downregulation is antigen-driven.17
Several exogenous and endogenous antigens have been proposed
including cytomegalovirus and heat shock proteins (HSPs).22,23
Strikingly, CD28null T cells that react to oxidized LDL (ox-LDL),
one of the antigens frequently implicated in atherosclerosis,
have not been described.23 An alternative hypothesis implicates in-
flammatory cytokines in CD28null T-cell expansion. CD28+ T-cell
clones from RA patients downregulated CD28 transcription follow-
ing TNF-a treatment in vitro.24 Conversely, infliximab triggered
CD28 re-expression in cells from patients with RA or unstable
angina (UA) in vitro;25,26 however, a different study found that eta-
nercept and infliximab did not affect the percentage of circulating
CD28null T cells in RA patients.27 Another mechanism that may
underlie CD28null T-cell expansion is resistance to apoptosis, due
to defects in molecules regulating apoptosis entry.13,14
It has been suggested that CD28null T cells may link innate and
adaptive immune responses. In line with this hypothesis, CD28null
T lymphocytes from patients with RA, psoriatic arthritis, or ankylos-
ing spondylitis (AS) were found to express Toll-like receptors TLR4
and TLR2 (the latter identified only in CD28null T cells in AS).28
The frequency of CD28null T-cell-expressing TLRs varied, with a
median of roughly 25% for CD28nullTLR4+ T cells and ,5% for
CD28nullTLR2+ T cells. In vitro treatment with TNF-a up-regulated
TLR4 and TLR2 expression on CD28null T cells from AS patients.
Contrastingly, TNF-a neutralization in AS patients decreased
expression of these TLRs on circulating CD28null T cells analysed
ex vivo.28 These receptors were functional as demonstrated by in-
creased perforin expression in CD28null T cells following stimulation
with the TLR4 and TLR2 agonist lipopolysaccharide.28 Of note, both
exogenous (microbial) and endogenous (e.g. HSP60) TLR agonists
have been described in atherosclerotic plaques, and TLR2/
4-mediated signals have been implicated in atherosclerosis.29
Whether TLR agonists contribute to CD28null T-cell activation
in situ in atherosclerotic lesions warrants further investigation. Over-
all, CD28null T cells produce high levels of inflammatory cytokines,
release cytotoxic molecules, and infiltrate atherosclerotic lesions,
wherein these features may allow them to contribute to the
on-going inflammatory response and plaque destabilization.
Regulatory CD41 T cells
The actions of pro-inflammatory T lymphocytes are normally
restrained by Treg cells. This specialized subset has critical roles in im-
mune homeostasis and preventing excessive immune responses.30,31
The most numerous and best-characterized are thymus-derived (natur-
ally occurring) Treg (identified as CD4+CD25highCD127lowFOXP3+ T
cells), as opposed to peripherally derived (induced) Treg, which origin-
ate from naive conventional T cells.31 Regulatory T cells comprise
around 5% of CD4+ T cells in the peripheral blood in humans, and
are characterized by the expression of the Forkhead box P3 transcrip-
tion factor (FOXP3), high CD25 levels, and low/no CD127 expres-
sion.30,31 Forkhead box P3 transcription factor is essential for Treg
development and suppressive function.32 Regulatory T cells employ
several mechanisms to suppress effector cells, among which are inhibi-
tory cell–cell interactions, release of anti-inflammatory cytokines (IL-10
and transforming growth factor-b, TGF-b), and disruption of metabolic
pathways (Figure 1).30,31 Regulatory T-cell impairment through numer-
ical and/or functional defects has been implicated in autoimmune dis-
eases including type I diabetes, systemic lupus erythematosus, RA,
multiple sclerosis, and inflammatory bowel disease.31
Evidence from animal models and patients with atherosclerosis
suggests an overall protective role for Treg. Depletion of Treg in
Apoe2/2 or Ldlr2/2 murine models aggravated atherosclerosis,
with Treg suggested to limit plaque inflammation and disease pro-
gression, although the mechanisms responsible remain poorly
defined.33 – 35 Data on Treg in human atherosclerosis are scant
and fraught with contradictory findings. Initial studies suggested
that the percentage of circulating CD4+CD25+ Treg is reduced in
ACS compared with SA patients and healthy individuals.36,37 Recent
studies failed to identify a consistent correlation between the per-
centage of circulating CD4+CD25highCD127low Treg and the sever-
ity of coronary artery disease,38 whereas other authors suggested
that CD4+FOXP3+ Treg reduction associates with an increased
risk for myocardial infarction.39 A likely explanation for these
contradictory findings is the inconsistent use of accurate markers
to identify Treg, particularly FOXP3, which remains the most specif-
ic marker for delineating Treg from other T cells in humans.32
A recent study quantified Treg by assessing the demethylation of
a conserved non-coding sequence in the FOXP3 locus (the Treg cell-
specific demethylated region), a feature essential for Treg
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suppressive function.30,31 Regulatory T cells identified by this meth-
od were reduced in ACS patients compared with controls, and their
reduction correlated with ACS severity.40 Even less information is
available on the suppressive function of Treg in patients with athero-
sclerosis. A report published in 2006 suggested a reduced suppres-
sive function of circulating CD4+CD25high Treg in ACS patients,36
but the study was insufficiently powered and did not employ a ro-
bust suppression assay.
Compared with other inflammed tissues, relatively low levels of
FOXP3+ Tregs were observed in human atherosclerotic plaques
(0.5–5% of CD3+ T cells), which may explain persistent inflamma-
tion in these lesions.41 Moreover, fewer FOXP3+ Treg were pre-
sent in vulnerable rather than stable plaques.42 Impaired Treg
survival has been suggested to have a role in this process, and in vitro
studies indicate that ox-LDL may trigger Treg apoptosis.43 Recent
data in ACS patients suggest that circulating CD4+ T cells may
have impaired ability to differentiate into Treg due to increased ex-
pression of protein tyrosine phosphatase PTPN22.44 A different
study suggested that CD4+CD25highCD127low Treg are enriched
in coronary thrombi adjacent to culprit lesions compared with per-
ipheral blood in ACS patients and that Treg from thrombi express a
restricted repertoire of antigen receptors compared with circulating
Treg.45 This suggests that circulating Treg may migrate into athero-
sclerotic lesions to control the inflammatory response, although fur-
ther work is warranted to clarify the contribution of circulating and
plaque-resident Treg in human atherosclerosis.
Potential strategies to target
CD28null T cells
Several attempts have been made to identify strategies to target
CD28null T cell (Figure 1). Initial studies on small numbers of patients
suggested that TNF-a blockade decreases circulating CD28null
T-cell number in RA and UA.25,26 However, recent studies failed
to show consistent depletion of this cell subset in RA patients
treated with infliximab or etanercept for 1 year.27 Whether
TNF-a inhibitors have beneficial effects in patients with coronary
atherosclerosis remains to be established.
Statins have also been suggested to reduce CD28null T cells in UA,
although the effect was modest (from 3 to 2.3% CD28null T cells,
P ¼ 0.022).46 Moreover, in a small study on patients with myocardial
infarction, Rosuvastatin treatment was linked to apoptosis of
CD28null T cells analysed ex vivo.47 We recently demonstrated
that Atorvastatin or Rosuvastatin failed to induce apoptosis in
CD28null T cells isolated from ACS patients.14 Our in vitro findings
are in line with previous reports that did not identify changes in
CD28null T-cell frequency after the acute coronary event in a
2-year follow-up study of ACS patients,13 indicating that statins do
not have major effects on CD28null T cells.
Protocols that modulate the inflammatory immune response by
blocking T-cell co-stimulation are being developed in autoimmunity
and other inflammatory disorders. Treatment with a CTLA-4Ig
fusion protein (Abatacept) that blocks CD28 ligation on T cells is
used in RA. This drug was found to reduce CD8+CD28null T cells,
but did not influence significantly CD4+CD28null T cells in RA
patients.48 Interestingly, in ACS, we found similar CTLA-4 levels
on CD4+CD28null and conventional CD4+CD28+ T lymphocytes,
while alternative co-stimulatory receptors OX40 and 4-1BB were
markedly up-regulated on CD4+CD28null T cells.10 This may explain
why Abatacept had minor effects on CD4+CD28null T cells in RA,
and suggest OX40 and 4-1BB blockade as a more rational approach.
Importantly, OX40 and 4-1BB are selectively expressed on acti-
vated/effector T cells, and are absent from naive/resting lympho-
cytes. Thus, blockade of OX40 and/or 4-1BB may allow specific
modulation of effector T cells that mediate tissue damage, while pre-
serving the ability of naive T lymphocytes to respond to exogenous
antigens. Tools to block OX40 and 4-1BB are being developed for
RA, multiple sclerosis, inflammatory bowel disease, asthma, trans-
plantation, and graft vs. host disease,49 which should facilitate their
use in atherosclerosis.
Recently, we have proposed another strategy for targeted modu-
lation of CD28null T cells that exploits molecules that regulate apop-
tosis. We demonstrated that the pro-apoptotic mitochondrial
protein Bim, which has central roles in controlling apoptosis induc-
tion, was reduced in CD28null T cells from ACS patients and this
associated with apoptosis resistance of these cells.14 Moreover,
we identified the proteasome, a protein degradation system, as a
key molecular switch that controls apoptosis of CD28null T cells
by degrading Bim and that, when targeted by proteasome-inhibiting
drugs, can restore apoptosis sensitivity of CD28null T cells. Encour-
agingly, proteasome inhibitors preferentially sensitized CD28null
T cells to apoptosis, indicating that the proteasome may be an
attractive target to enable selective elimination of CD28null T cells,
while sparing conventional CD28+ T lymphocytes and avoiding
bystander immunosuppression.
Recent studies implicate endogenous microRNAs (miRs) in the
regulation of T-cell development, differentiation, and function, and
on-going research is trying to harness miRs to target inflammatory
responses in atherosclerosis.50 Moreover, miRs have important
roles in the pathophysiology of cardiovascular diseases. Cardiovas-
cular patients have altered patterns of circulating miRs, and potential
diagnostic and therapeutic applications are under investigation.51 Of
particular relevance to T cells is miR-29 that specifically inhibits
IFN-g production from CD4+ T cells by targeting the transcription
factors T-bet and Eomes.52 MicroRNA-155 has also been implicated
in the generation of Th1 cells, as T lymphocytes from miR-1552/2
mice showed skewing towards Th2 with predominant production of
IL-4 and IL-10 and deficient IFN-g secretion.53 Interestingly,
miR-155 was also implicated in Treg survival.54 MicroRNA-146a is
upregulated in ACS and promotes Th1 differentiation through
T-bet induction.55 The precise contribution of these miRs to the
generation of CD28null T lymphocytes and IFN-g production is
currently unknown. A better characterization of the precise
mechanisms that drive the inflammatory/cytotoxic functions and
expansion of CD28null T cells may unveil additional strategies to
modulate this CD4+ T-cell subset in ACS patients.
Regulatory T cell-based therapies
for atherosclerosis
Given their pivotal roles in immune homeostasis and prevention of
excessive/harmful immune responses, substantial research efforts
are focused on developing Treg-based therapies to reset dysfunc-
tional immune responses in inflammatory diseases. Clinical trials
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employing Treg are on-going in solid-organ transplantation, type I
diabetes, and graft vs. host disease.56 These trials primarily use puri-
fication of naturally occurring FOXP3+ Treg from patients, followed
by in vitro expansion and reinfusion. Protocols involving in vivo ma-
nipulation of Treg subsets (expansion of naturally occurring Treg
or conversion of antigen-specific conventional T cells into Treg)
are also explored (Figure 1). Of note, adoptive transfer of Treg in
animal models markedly reduced atherosclerosis, suggesting that a
similar strategy may be beneficial in patients.33 Moreover, several
murine studies successfully demonstrate that in vivo induction of
polyclonal or antigen-specific Treg (e.g. ox-LDL, ApoB100, and
HSP60) reduced atherosclerosis development and/or progres-
sion.57 One of the most promising antigens is apolipoprotein
B100 (ApoB100), with several studies showing that ApoB100
peptide-based vaccines inhibited atherosclerosis in mice through
Treg induction.58,59 Vaccination protocols using ApoB100 are being
developed for first-in-human clinical trials.
Immunosuppressive drug treatment has been suggested to affect
Treg in atherosclerotic plaques. A randomized control trial on a
small group of patients with atherosclerotic carotid artery stenosis
found that mycophenolate mofetil, an immunosuppressive drug
used to prevent allograft rejection due to its ability to inhibit acti-
vated T-cell proliferation, caused not only a reduction in activated
(CD3+CD69+) T cells, but also an increase in CD3+Foxp3+ in
carotid atherosclerotic lesions.60
The safety and efficacy of Treg-based therapies in human athero-
sclerosis has not yet been investigated and important issues remain
to be addressed for optimal design of protocols utilizing adoptive
transfer of Treg or vaccines that induce Treg in vivo. An important
challenge for Treg-based immunotherapy remains the stability of
Treg during in vitro manipulation and following reinfusion in patients
with on-going inflammation. Several studies suggest that Treg may
lose FOXP3 expression during in vitro culture or following reinfusion
into hosts, which associates with decreased suppression, and
possibly Treg conversion into pathogenic T cells.32 Moreover, to
efficiently break the chronic inflammation cycle, Treg-based
therapies may not be sufficient and may need to be combined
with strategies that deplete/modulate pro-inflammatory T cells.
Future directions
On-going clinical trials testing anti-inflammatory therapies in
patients with coronary atherosclerosis target inflammatory cyto-
kines (IL-1b, IL-6, and TNF-a).4 Although these trials will bring
valuable information on the role of inflammation in atherosclerosis,
it is clear that both pro-atherogenic and atheroprotective immune
networks operate in this disease. Moreover, considering the com-
plexity and heterogeneity of atherosclerosis in humans, a more
targeted immune-modulatory approach, adapted to the predomin-
ant pathogenic mechanisms, may be required. Current long-term
immunomodulation protocols harbour considerable side effects
(infections, immunosuppression, and malignancy). Therefore, care-
ful assessment of benefit/risk profile and development of safer,
more targeted immunomodulation therapies are required in athero-
sclerosis, wherein the inflammatory process is often more discreet
than in other chronic inflammatory disorders. Although translation
of recent advances on the role of T lymphocytes and other immune
cells in atherosclerosis is complex and fraught with challenges, tar-
geted immunomodulation harbours high potential to complement
and synergise with drugs/interventions currently used in athero-
sclerosis patients. Encouragingly, antibodies and other biological
or pharmacological reagents that modulate T and B lymphocytes
or molecules that regulate their function have been incorporated
with promising results in the clinical armamentarium in cancer, auto-
immunity, and transplantation, which lends hope to their future ap-
plications in atherosclerosis.
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